Researchers at the Perelman School of Medicine at the University of Pennsylvania have made a significant breakthrough in personalized medicine and cancer treatment. By using patient-derived glioblastoma (GBM) organoids, they have developed a method to model patient responses to CAR-T cell therapy
Recent research from Weill Cornell Medicine has unveiled a promising preclinical discovery that could significantly enhance the effectiveness of cancer immunotherapy for B-cell non-Hodgkin lymphomas (B-NHL). The study focuses on the use of EZ## inhibitors, an emerging class of anticancer drugs, in
In a remarkable breakthrough in breast cancer treatment, a novel cell-based immunotherapy developed by Dr. Gary Koski from Kent State University and Dr. Brian J. Czerniecki from the Moffitt Cancer Center has been recently accepted for publication in JAMA Oncology. This innovative approach harnesses
For lymphoma patients, particularly those facing relapsed or refractory large B cell lymphoma (LBCL), CAR T cell therapy represents a beacon of hope. This promising treatment, epitomized by Breyanzi (lisocabtagene maraleucel), offers a new avenue for those who have exhausted conventional treatment
Synthetic biology represents a revolutionary discipline that applies engineering principles to biology, aiming to develop cells into sophisticated micro-factories capable of producing essential materials. With the potential to spearhead advancements across numerous industries—including medicine, a
In a groundbreaking development, QIMR Berghofer has made significant strides in combating severe viral infections in immunocompromised patients through their pioneering cell therapy. This innovative treatment has proven effective in 46 out of 71 patients, resulting in a notable 65% success rate.
